OF THE MEDICINES
Micro-immunotherapy medicines are primarily made up of cytokines (such as interleukins, chemokines and growth factors) and specific nucleic acids (SNA®) in low concentrations (micro-doses). These same molecules are used by the immune system cells themselves to organise the immune response when faced with aggressions.
The majority of ingredients in micro-immunotherapy medicines are produced using biotechnology techniques.
The principal cytokines currently known are interleukins (classified from IL-1 to IL-35), interferons (IFN-α, β and γ), growth factors (CSF, TGF, etc.), tumour necrosis factors (TFN-α y,–β) and chemokines. These are specialised proteins which organise communication between immune system cells (such as lymphocytes, macrophages, neutrophils, etc.), thereby enabling the coordination of different processes such as their activation, proliferation, recruitment, etc. This is why they are commonly known as immune “messengers”. They can have an effect on the same cells that have produced them (autocrine) or even act remotely on other organs or tissues (endocrine effect).
Given their informational role, cytokines form the basis of micro-immunotherapy medicines. They are used to “readjust” the immune response and help the body return to its natural balanced state.
SPECIFIC NUCLEIC ACIDS (SNA®)
The SNA® present in micro-immunotherapy medicines are small synthesised oligonucleotides whose objective is to counteract the gene expression involved in a particular pathology or disorder. For example, in a viral infection, their objective would be to reduce the gene expression which is essential for the replication of the virus.
The therapeutic innovation which SNA® represent has been patented by Labo’Life.